3i is to sell its stake in Domantis, a developer of next generation antibody therapies to GlaxoSmithKline in an all cash deal valuing the company at £230m. The exit is generating an IRR in excess of 100% on 3i's investment. Other investors in Domantis include Gray Ghost LLC and Albany Ventures and MVM Life Science Partners.
This is the second deal inked by the GP via Wisequity V, which closed on its €260m hard-cap in July 2019
Pascal Meysson joins from Alcentra and has previous experience at Deutsche Bank and Charterhouse
Mirabaud is reportedly planning to invest via its Living Heritage private equity fund
HIG invested from its Growth Buyout Equity Fund III to acquire Vernacare from Palatine